Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HTR1A | P08908 | 18/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 18/20 | 0.62 |
| ▸ | HTR1B | P28222 | 18/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 18/20 | 0.62 |
| ▸ | ADRA1B | P35368 | 18/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | DRD3 | P35462 | 2/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3457276 | 0.88 | HTR1A (0.64) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL14142931 | 0.88 | HTR1A (0.62) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL6993825 | 0.85 | HTR1A (0.57) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL6993267 | 0.83 | HTR1A (0.59) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL7522252 | 0.83 | ALDH1A1 (0.71) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4493613 | 0.81 | SIGMAR1 (0.53) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL6999544 | 0.81 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2HTR1AADRA1D | |
| SCHEMBL6998104 | 0.80 | HTR1A (0.74) | HTR1AADRA1DHTR1BADRA1AADRA1B | |
| SCHEMBL4511186 | 0.80 | SMN1; SMN2 (0.65) | NPC1RAB9ASMN1; SMN2HTR1AADRA1D | |
| SCHEMBL7720235 | 0.79 | HTR1A (0.78) | HTR1AADRA1DHTR1BADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196301-A1 | USE OF BINDING PARTNERS FOR 5-HT5 RECEPTORS FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-08-02 | — | — | US | disclosed |
| EP-2266570-A1 | Use of binding partners for 5-HT5 receptors for treating neurodegenerative and neuropsychiatric disorders | Abbott GmbH & Co. KG (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-7491729-B2 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBOTT GMBH & CO. KG (DE) | 2009-02-17 | — | — | US | disclosed |
| EP-1572698-B1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO¬2,3-D PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20040202656-A1 | Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-10-14 | — | — | US | disclosed |
| US-6750221-B1 | IN VITRO BINDING STUDIES TO SCREEN COMPOUNDS FOR SELECTIVITY OF 5HT-5 OVER 5HT-1A RECEPTORS | BASF AKTIENGESELLSCHAFT (DE) | 2004-06-15 | — | — | US | disclosed |
| EP-0927184-B1 | 3-SUBSTITUTED PYRIDO 4',3':4,5]THIENO 2,3-D]PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE | ABBOTT GMBH & CO KG (DE) | 2003-10-22 | — | — | EP | disclosed |
| US-6387912-B1 | STROKE THERAPY | BASF AKTIENGESELLSCHAFT (DE) | 2002-05-14 | — | — | US | disclosed |
| US-6222034-B1 | AS SEROTININ RECEPTOR ANTAGONISTS; FOR THERAPY OF DEPRESSION, CENTRAL NERVOUS SYSTEM DISORDERS | BASF AKTIENGESELLSCHAFT (DE) | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040202656-A1 | Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders | HTR5A, GRM5, GRIK5 | NPC1 2482/4885RAB9A 2492/4885SMN1; SMN2 3377/4885 |
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | HTR3C, DRD3, HTR4 | NPC1 2892/4885RAB9A 2126/4885SMN1; SMN2 4220/4885 |
| US-20120196301-A1 | USE OF BINDING PARTNERS FOR 5-HT5 RECEPTORS FOR THE TREATMENT OF NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | HTR5A, GRM5, GRIK5 | NPC1 2482/4885RAB9A 2492/4885SMN1; SMN2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.